| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7024
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-39 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7024 |
| filingDate |
2003-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6fac750a3946f7197068fcfdf45ab033 |
| publicationDate |
2004-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2004091465-A1 |
| titleOfInvention |
Therapeutic antiangiogenic compositions and methods |
| abstract |
An inhibitor of endothelial cell proliferation, capable of inhibiting angiogenesis and causing tumor regression, that is approximately 20 kDa and corresponds to a C-terminal fragment of collagen type XVIII, and methods of treating angiogenesis-related disease are provided. The inhibitor is known as endostatin. In a preferred embodiment, endostatin is administered to a patient in a pharmaceutical formulation. The pharmaceutical formulation preferably comprises endostatin combined with sucrose octasulfate. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10813552-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9474448-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9498135-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9629554-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10351613-B2 |
| priorityDate |
2002-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |